Disclosures for "High-Efficacy Therapies Reduce Clinical and Radiological Events More Effectively than Traditional Treatments in Neuromyelitis Optica Spectrum Disorder")
-
Miss Moog has nothing to disclose.
-
Mr. Smith has nothing to disclose.
-
Mr. McCreary has nothing to disclose.
-
Katy Burgess has nothing to disclose.
-
Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Celgene. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for VielaBio.